Drugs / Dihydralazine
Dihydralazine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05230901 | Feb 2022 → Jun 2025 | aortic valve stenosis | University Medical Center Goettingen | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00311974 | Apr 2006 → Nov 2007 | — | Regional Hospital Holstebro | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dihydralazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05230901 ↗ |
| Known as | Dihidralazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL35505 ↗ |
| Known as | DIHYDRALAZINE SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL35505 ↗ |
| Known as | Dihydralazine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL35505 ↗ |
| Known as | NSC-526654 | ChEMBL registry synonym — accepted as the source's own label CHEMBL35505 ↗ |
| Modality | Small molecule | — CHEMBL35505 ↗ |
| Route | Oral | “dihydralazine (2x12.5 mg/d p.o. in slow acethylators” NCT05230901 ↗ |